The effect of Modafinil on improving consciousness with COVID-19

Phase 2

Recruiting

• Conditions: Coronavirus 2019.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20170903036041N3
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 May 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Confirm patient with clinical feature, laboratory and chest CT scan
Having mild decrease level of consiousness, drowsiness to deep coma

Exclusion Criteria

History of seizure
Clinical feature accompanied after drug cosumption
Drug side effects

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of consiousnesa. Timepoint: On admission and after 3 days. Method of measurement: Glasgow Coma Scale.;Headache. Timepoint: On admission and after 3 days. Method of measurement: Interview with the patient.;Seizure. Timepoint: On admission and after 3 days. Method of measurement: Observation, examination and recording data.

Secondary Outcome Measures

Name	Time	Method
Biochemical laboratory data. Timepoint: Before intervention and daily in duration of intervention. Method of measurement: Laboratory kit.